Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study

Table 1 Baseline characteristic of studied participants

Variables	Group A (n = 88) Metformin + Sitagliptin	Group B (n = 44) Metformin + Empagliflozin	P value*
Age (years) mean ± SD	50.6 ± 10.5	44.7 ± 10.7	0.027*
Variables			P value**
Male / Female	43 / 45 = 48.8%	24 / 20 = 54.5%	0.538**
Hypertension	37 = 42%	16 = 36.3%
Anti HTN medications			P value**
Angiotensin-converting enzyme inhibitors	11 = 12.5%	2 = 4.5%	0.148
Calcium Channel Blocker	09 = 10.2%	07 = 15.9%	0.346
Angiotensin II receptor blockers	18 = 20.4%	14 = 31.8%	0.151

^*P value calculated using Independent sample T test, keeping P value ≤ 0.5 as significant
^**P value calculated using Pearson Sq. Test, keeping P value ≤ 0.5 as significant

ISSN: 1472-6823